Skip to Content


Generic Name: Abciximab
Class: Platelet-aggregation Inhibitors
- Antithrombotic Agents
- Platelet-aggregation Inhibitors
- GP IIb/IIIa Receptor Inhibitors
Chemical Name: Human mouse monoclonal c7E3 clone p7E3VHhCgamma4 Fab fragment anti-human glycoprotein IIb/IIIa receptor immunoglobulin G disulfide with human-mouse monoclonal c7E3 clone p7E3vkhCk light chain
CAS Number: 143653-53-6

Medically reviewed by Last updated on Sep 18, 2017.


Platelet aggregation inhibitor; a platelet glycoprotein (GP IIb/IIIa)-receptor inhibitor.1 2 4 5

Uses for ReoPro

Acute Ischemic Complications of PCI

Adjunct to anticoagulant therapy (e.g., heparin [referring throughout this monograph to unfractionated heparin], low molecular weight heparin), aspirin, and a P2Y12 platelet adenosine diphosphate (ADP)-receptor antagonist (e.g., clopidogrel, prasugrel, ticagrelor) to prevent acute cardiac ischemic complications in patients undergoing PCI or in patients with non-ST-segment-elevation acute coronary syndromes (NSTE ACS; unstable angina or non-ST-segment-elevation MI [NSTEMI]) not responding to conventional medical therapy in whom PCI is planned within 24 hours.1 2 4 5 7 10 11 91 994 995 1100

Adjunctive therapy with a GP IIb/IIIa-receptor inhibitor can reduce the incidence of cardiac ischemic events, including subsequent MI and death, in patients with NSTE ACS undergoing PCI and in patients without these conditions undergoing PCI.10 11 17 47 48 49 50 51

Safety and efficacy in patients not undergoing PCI not established.1 1016

The American College of Cardiology Foundation (ACCF), AHA, the Society for Cardiovascular Angiography and Interventions (SCAI), and other experts currently do not recommend routine use of GP IIb/IIIa-receptor inhibitors in patients with ST-segment elevation MI (STEMI) undergoing PCI; however, selective use of these drugs as an adjunct to heparin may be reasonable in certain high-risk patients (e.g., those with large anterior MI and/or large thrombus).994 1016

ACCF/AHA/SCAI state that administration of a GP IIb/IIIa-receptor inhibitor at the time of PCI as an adjunct to heparin may be particularly useful in patients with NSTE ACS who have high-risk features (e.g., elevated troponin) and are not receiving bivalirudin and are not adequately pretreated with clopidogrel.994

Regarding choice of GP IIb/IIIa-receptor inhibitor in patients undergoing PCI, IV abciximab, “double-bolus” IV eptifibatide, and high-dose tirofiban given by direct IV injection all produce a high degree of platelet inhibition and reduce ischemic complications.994

Non-ST-Segment-Elevation Acute Coronary Syndromes

Has been used in patients with unstable angina or NSTEMI (i.e., NSTE ACS) managed with conservative medical therapy only; however, manufacturer and some clinicians state that safety and efficacy of abciximab not established in such patients who are not undergoing PCI.1 991

A GP IIb/IIIa-receptor inhibitor may be used in conjunction with aspirin prior to diagnostic angiography (“upstream”) in patients with NSTE ACS in whom an initial invasive management strategy is planned; however, IV eptifibatide or tirofiban is the preferred GP IIb/IIIa inhibitor for this use.991 Abciximab is recommended in this situation only if there is no appreciable delay before angiography and PCI is likely to be performed.991

ReoPro Dosage and Administration


  • Discontinue infusion in patients in whom PCI has failed.1

Adjunctive Antithrombotic Therapy: General Considerations

  • Used in conjunction with aspirin and heparin in clinical studies.1

  • Dosage of heparin required to maintain an appropriate activated clotting time (ACT) during concomitant therapy with abciximab may be lower than with heparin monotherapy.19 994 (See Specific Drugs under Interactions.)

Adjunctive Antithrombotic Therapy When Used to Prevent Acute Ischemic Complications of PCI

  • Aspirin: In clinical studies, patients received 325 mg 2 hours prior to PCI and daily thereafter.1 77 ACCF/AHA/SCAI recommends that aspirin 325 mg be given prior to PCI in patients not already receiving maintenance aspirin therapy.994 Patients already receiving maintenance aspirin therapy should receive a dose of 81–325 mg before the procedure.994

  • P2Y12-receptor antagonist: A loading dose of clopidogrel, prasugrel, or ticagrelor also is recommended prior to PCI in those undergoing stent placement.994

  • Heparin sodium: In clinical studies, patients received 70 units/kg if baseline ACT <150 seconds, 50 units/kg if baseline ACT was 150–199 seconds, or no heparin if baseline ACT ≥200 seconds; additional injections of 20 units/kg were given to maintain an ACT of ≥200 seconds during the procedure.1 Experts suggest use of lower dosages of concomitant IV heparin sodium (e.g., 50–70 units/kg) given 6 hours prior to PCI and targeted to an ACT of ≥200 seconds.10 12 16 19 45 46 77 994 (See Laboratory Monitoring under Cautions.) Postprocedural use of heparin generally not recommended.1 10 22 77


IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV injection followed by IV infusion using a controlled-infusion device (e.g., pump).1

Do not shake vial.1

Filter injection upon dilution, prior to IV administration, or during IV infusion using a sterile, nonpyrogenic, low-protein-binding filter (0.2 or 5 µm).1 7

For IV injection, withdraw appropriate dose into syringe and filter injection prior to administration.1

Discard unused portion.1

Do not admix or administer other drugs in the same IV line with abciximab injection or infusion.1


For IV infusion, withdraw appropriate dose into syringe and inject into an appropriate container of 0.9% sodium chloride or 5% dextrose injection.1

Rate of Administration

For IV injection, administer over at least 1 minute.1 7



Acute Ischemic Complications of PCI

Patients undergoing PCI: 0.25 mg/kg by IV injection 10–60 minutes prior to PCI,1 7 followed by IV infusion of 0.125 mcg/kg per minute (maximum of 10 mcg/minute) for 12 hours.1

Patients scheduled to receive PCI within 24 hours: 0.25 mg/kg by IV injection, followed by IV infusion of 10 mcg/minute for 18–24 hours, concluding 1 hour after procedure.1 4

Prescribing Limits


Acute Ischemic Complications of PCI

Patients undergoing PCI: Maximum 10 mcg/minute (as IV infusion) for 12 hours.1

Special Populations

No special population dosage recommendations at this time.1

Cautions for ReoPro


  • Bleeding diathesis, active internal bleeding, or recent (within 6 weeks) clinically important GI or genitourinary bleeding.1

  • Severe uncontrolled hypertension.1

  • Recent (within 6 weeks) major surgery or trauma.1

  • History of cerebrovascular accident (CVA) in preceding 2 years or CVA with serious substantial residual neurologic deficit.1

  • Recent (within previous 7 days) oral anticoagulant therapy unless prothrombin time (PT) is ≤1.2 times control value.1

  • Thrombocytopenia (platelet count <100,000/mm3).1

  • Intracranial neoplasm.1

  • Arteriovenous malformation or aneurysm.1

  • Use of IV dextran prior to or during PCI.1

  • Presumed or documented history of vasculitis.1

  • Known hypersensitivity to any ingredient in the formulation or to murine proteins.1 9



Hematologic Effects

Risk of major bleeding (e.g., intracranial hemorrhage, genitourinary or GI bleeding, bleeding at arterial access site) and minor bleeding (e.g., spontaneous gross hematuria, spontaneous hematemesis); may require blood or platelet transfusions.1 2 4 5 (See Bleeding Precautions and see Laboratory Monitoring under Cautions.)

Pulmonary alveolar hemorrhage reported rarely.1

Increased risk of major bleeding observed in patients weighing ≤75 kg;1 4 5 during concomitant thrombolytic therapy;1 when PCI is performed within 12 hours of onset of symptoms of MI;1 following prolonged (>70 minutes) PCI;1 or following failed PCI.1 9

If bleeding cannot be controlled by pressure, discontinue abciximab and concomitant heparin immediately.1

Sensitivity Reactions

Hypersensitivity Reactions

Possible anaphylaxis.1 If anaphylaxis occurs, discontinue abciximab immediately and initiate appropriate treatment; drugs for treatment of hypersensitivity reactions (e.g., epinephrine, dopamine, theophylline, antihistamines, corticosteroids) should be immediately available.1

Formation of human antichimeric antibody (HACA) reported.1 3 8 16 22 23 54 63 65 Possible hypersensitivity reactions (including anaphylaxis), thrombocytopenia, or diminished antithrombotic effect if abciximab is readministered or if monoclonal antibodies are administered in patients with HACA titers.1

General Precautions

Bleeding Precautions

To reduce risk of bleeding, adhere to strict anticoagulation guidelines; use a short course of low-dose, weight-adjusted heparin; avoid vascular and other trauma; carefully manage vascular (e.g., femoral artery) access site; and monitor all potential bleeding sites during and following treatment.1 44 60

Use caution in the placement, maintenance, and removal of vascular access sheath; avoid femoral vein sheath placement.1 When inserting sheath, puncture only anterior wall of femoral artery; avoid Seldinger (through and through) technique.1 Observe appropriate precautions while sheath is in place (e.g., complete bed rest, elevation of head ≤30°, restrain limb in which sheath is inserted, frequent monitoring of vascular access site and distal pulse in the involved limb).1 Following PCI, discontinue heparin immediately; remove arterial sheath within 6 hours following PCI (at least 2 hours after discontinuation of heparin) if aPTT ≤50 seconds or ACT ≤175 seconds.1 Following sheath removal, apply pressure to femoral artery for at least 30 minutes to achieve hemostasis.1 Measure and monitor hematomas for enlargement.1

To avoid vascular and other trauma, minimize arterial or venous punctures, IM injections, cutdown sites, and use of nasotracheal intubation, nasogastric tubes, urinary catheters, and automatic BP cuffs; avoid establishment of IV access at noncompressible sites (e.g., subclavian or jugular veins); consider using an indwelling venipuncture device (e.g., heparin lock) for drawing blood; document and monitor vascular puncture sites; and remove dressings gently and carefully.1

If emergency surgery is needed, discontinue abciximab.1


Risk of thrombocytopenia.1 Severe thrombocytopenia (platelet count <20,000/mm3)19 46 66 reported more frequently than with tirofiban.1 32 54 67 68

Determine platelet count prior to treatment, at 2–4 hours following initial IV injection, and at 24 hours following initiation of therapy or prior to discharge, whichever occurs first.1 9 Consider possibility of pseudothrombocytopenia or heparin-induced thrombocytopenia (in patients receiving concomitant heparin therapy).1 14 47 54 59 70 Exclude pseudothrombocytopenia caused by an in vitro anticoagulant interaction by sampling blood in tubes containing edetate disodium (EDTA), citrate, or heparin.1 A low platelet count in the presence of EDTA but not in the presence of heparin and/or citrate supports of a diagnosis of pseudothrombocytopenia.1

If true thrombocytopenia is verified, discontinue abciximab and initiate appropriate treatment and monitoring.1 Platelet transfusions may partially restore platelet function.1

Possible increased incidence and severity of thrombocytopenia following readministration.1

Contraindicated in patients with platelet counts <100,000/mm3.1

Laboratory Monitoring

Prior to administration, obtain platelet count, PT, ACT, and aPTT.1

Monitor platelet count during and after treatment.1 (See Thrombocytopenia under Cautions.)

When abciximab is initiated 18–24 hours prior to PCI, maintain aPTT between 60–85 seconds.1 During PCI, maintain ACT ≥200 seconds.1 10 12 16 19 45 46 77 If anticoagulation is continued following PCI, maintain aPTT between 55–75 seconds.1

Monitor aPTT or ACT prior to arterial sheath removal; do not remove sheath unless aPTT ≤50 seconds or ACT is 150–180 seconds (approximately 6 hours after PCI).1

Specific Populations


Category C.1


Not known whether abciximab is distributed into milk.1 Use with caution.1 9

Pediatric Use

Safety and efficacy not established in children <18 years of age.1 9

Geriatric Use

No substantial differences in safety and efficacy in patients 65–74 years of age relative to younger adults.1 Insufficient experience in patients ≥75 years of age to determine whether these patients respond differently than younger adults.1

Common Adverse Effects

Bleeding, back pain, hypotension, nausea, chest pain, vomiting, headache, bradycardia, puncture site pain, abdominal pain, peripheral edema.1

Interactions for ReoPro

No formal drug interaction studies to date.1

Specific Drugs




Anticoagulants, oral

Potential increased risk of bleeding1

Use with caution1


Increased risk of bleeding1

Concomitant use contraindicated1


Potential increased risk of bleeding1

Use with caution1


Increased risk of bleeding1

Monitor aPTT or ACT during therapy1


Potential increased risk of bleeding1

Use with caution1

Thrombolytics (e.g., reteplase)

Increased risk of major bleeding1

Weigh risk against anticipated benefit of concomitant therapy1


Potential increased risk of bleeding1

Use with caution1

ReoPro Pharmacokinetics



Maximal inhibition of platelet aggregation occurs within 10 minutes following IV administration.1


Bleeding time returns to ≤12 minutes within 12–24 hours following discontinuance of infusion.1 Platelet function generally recovers within 48 hours.1



Not known whether abciximab is distributed into breast milk or is absorbed systemically after ingestion.1



Initial half-life is <10 minutes; second phase half-life is about 30 minutes.1 Abciximab remains in circulation for ≥15 days in a platelet-bound state.1





2–8°C.1 Do not freeze.1


For information on systemic interactions resulting from concomitant use, see Interactions.


No incompatibilities observed with glass bottles, PVC bags, or IV administration sets.1

Solution Compatibility1

No incompatibilities observed with IV fluids.1


Dextrose 5%

Sodium chloride 0.9%

Drug Compatibility

No incompatibilities observed with commonly used cardiovascular drugs.1 Nevertheless, administer abciximab in separate IV line whenever possible; do not mix with other drugs.1

Y-Site CompatibilityHID



Atropine sulfate111


Diphenhydramine HCl111

Fentanyl citrate111

Metoprolol tartrate111

Midazolam HCl111


  • Fab fragment of chimeric human-murine monoclonal immunoglobulin antibody 7E3.1 2 3 4 5 6

  • Binds selectively to platelet GP IIb/IIIa receptors and reversibly inhibits platelet aggregation (by preventing binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa receptors).1 2 4 5

Advice to Patients

  • Risk of serious bleeding or hemorrhage.1 4 5 9

  • Importance of close laboratory monitoring.1

  • Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses (e.g., cardiovascular disease).1

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1

  • Importance of advising patients of other important precautionary information.1 (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.



Dosage Forms


Brand Names



Injection, for IV use

2 mg/mL (10 mg)



AHFS DI Essentials™. © Copyright 2019, Selected Revisions September 18, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.


1. Eli Lilly and Company. ReoPro (abciximab) injection for intravenous administration prescribing information. Indianapolis, IN; 2005 Jun. 3.

2. Topol EJ, Califf RM, Weisman HF et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994; 343:881-5.

3. Simoons ML, de Boer MJ, van den Brand MJ et al. Randomized trial of GpIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994; 89:596-603.

4. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994; 330: 956-61.

5. Anon. Centocor will begin shipping Reopro to Lilly in early January: Reopro is the first GpIIbIIIa antagonist for PTCA patients at high risk for ischemic complications. F-D-C Rep. 1995 Jan:16-7.

6. Tcheng JE, Ellis SG, George BS et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994; 90:1757-64.

7. Eli Lilly and Company, Indianapolis, IN: Personal communication.

8. Ellis SG, Tcheng JE, Navetta FI et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Cor Art Dis. 1993; 4:167-75.

9. Eli Lilly and Company, Indianapolis, IN: Personal communication.

10. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997; 336:1689-96.

11. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997; 349:1429-35.

12. Kleiman NS. A risk-benefit assessment of abciximab in angioplasty. Drug Saf. 1999; 20:43-57.

13. Detre KM, Holmes DR Jr, Holubkov R et al. Incidence and consequences of periprocedural occlusion: the 1985–1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1990; 82:739-50.

14. Lincoff AM. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Am J Cardiol. 1998; 82:36P-42P.

15. Alexander JH, Harrington RA. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A, and PURSUIT. Drugs. 1998; 56:965-76.

16. White H. Unmet therapeutic needs in the management of acute ischemia. Am J Cardiol. 1997; 80(Suppl 4A):2b-10b.

17. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol. 1996; 78(Suppl 3A):35-40.

19. Reviewers’ comments (personal observations) on eptifibatide.

20. Sebastian M, Makkar R. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging. Drugs & Aging. 1999; 15:207-18.

21. Foster RH, Wiseman LR. Abciximab: an updated review of its use in ischaemic heart disease. Drugs. 1998; 56:629-65.

22. Anon. Randomised placebo-controlled trial of effect of eptifibatide on complication of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997; 349:1422-8.

23. Tcheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Am J Cardiol. 1997; 80(Suppl 4A):21B-8B.

25. Agency for Health Care Policy and Research. Diagnosing and managing unstable angina. 1994. (AHCPR publication no. 94-0603)

27. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308:81-106.

28. Cairns JA, Gent M, Singer J et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med. 1985; 313:1369-75.

29. Lewis HD, Davies JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983; 309:396-403.

30. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990; 336:827-30.

31. Théroux P, Waters D, Qiu S et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993; 88(5 Pt 1):2045-8.

32. Théroux P, Ouimet H, McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988; 319:1105-11.

33. Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998; 97:1195-1206.

34. Tonkin AM, Aroney CN. Guidelines for managing patients with unstable angina: rating the evidence and rationale for treatment. Med J Aust. 1997; 16:644-7.

35. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997; 337: 447-52.

36. Armstrong PW. Heparin in acute coronary disease-requiem for a heavyweight? N Engl J Med. 1997; 337:492-4. (IDIS 389821)

37. Swahn E, Wallentin L for the FRISC study group. Low-molecular weight heparin (fragmin) during instability in coronary artery disease (FRISC). Am J Cardiol. 1997; 80(Suppl. 5A):25E-9E.

38. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation. 1999; 100:437-44.

39. Théroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am Heart J. 1997; 134:S62-70.

40. Cohen M, Adams PC, Gareth P et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end points analysis for the ATACS trial. Circulation. 1994; 89:81-8.

41. Oler A, Whooley MA, Oler J et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA. 1996; 276:811-5.

43. Topol EJ. Targeted approaches to thrombus formation: an end to the shotgun approach. Clin Cardiol. 1997; 20(Suppl I):I-22-6.

44. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995; 332:1553-9.

45. Tcheng JE, Harrington RA, Kottke-Marchant K et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention. Circulation. 1995; 91:2151-7.

46. Cor Therapeutics, South San Francisco, CA, and Key Pharmaceuticals, Kenilworth, NJ: Personal communication on eptifibatide.

47. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998; 98:2629-35.

48. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997; 96:1445-53.

49. Adgey AAJ. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J. 1998; 135:S43-55.

50. Dobesh PP, Latham KA. Advancing the battle against ischemic syndromes: a focus on the GP-IIb/IIIa inhibitors. Pharmacotherapy. 1998; 18:663-85.

51. Kong DF, Califf Rm, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ishemic heart disease. Circulation. 1998; 98:2829-35.

52. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA. 1999; 281:1407-14.

53. Giugliano RP, Hyatt RR. Thrombocytopenia with GP IIb/IIIa inhibitors: a meta-analysis. J Am Coll Cardiol. 1998; 31(Suppl 2A):185A.

54. Ferguson JJ, Kereiakes DJ, Adgey AAJ et al. Safe use of platelet GP IIb/IIIa inhibitors. Am Heart J. 1998; 135:S77-89.

55. Quinn M, Fitzgerald DJ. Long-term administration of glycoprotein IIb/IIIa antagonists. Am Heart J. 1998; 135:S113-8.

56. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb/IIIa blockers. Lancet. 1999; 353:227-31.

57. Key Pharmaceuticals. Integrelin™ (eptifibatide) injection prescribing information. Kenilworth, NJ; 1998 May.

59. Merck & Co. Aggrastat (tirofiban hydrochloride) injection premixed and injection prescribing information. West Point, PA; 1999 Jul.

60. Reviewers’ comments (personal observations) on tirofiban.

61. Merck & Co., West Point, PA: Personal communication on tirofiban.

62. Peerlinck, De Lepeleire I, Goldberg M et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 1993; 88:1512-7.

63. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997; 80(Suppl 4A):11b-20b.

64. Key Pharmaceuticals. Integrilin™ (eptifibatide) product monograph. Kenilworth, NJ; 1998 Aug.

65. Le Breton H, Plow EF, Topol EJ et al. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol. 1996; 28:1643-51.

66. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998; 339:436-43.

67. Kereiakes DJ, Kleiman NS, Ambrose J et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996; 27:536-42.

68. Ferguson JJ, Waly HM, Wilson JM. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Am Heart J. 1998; 135:S35-42.

69. Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute coronary syndromes. Am J Cardiol. 1997; 80(Suppl 4A):34b-8b.

70. Merck & Co. Product information form for American hospital formulary service: Aggrastat (tirofiban hydrochloride). West Point, PA; 1998.

72. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995; 332:1553-9.

73. Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA. 1997; 278:479-84.

74. Lincoff AM, Tcheng JE, Califf RM et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one year outcome in the EPILOG trial. Circ. 1999; 99:1951-8.

75. Ghaffari S, kereiakes DJ, Lincoff AM et al. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional atherectomy. Am J Cardiol. 1998; 82:7-12.

76. Keriakes D, Lincoff AM, Miller DP et al. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. Circ. 1998; 97:857-64.

77. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998; 352:87-92.

78. Lincoff AM, Califf RM, Moliterno DJ et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet gycoprotein IIb/IIIa receptors. N Engl J Med. 1999; 341:319-27.

79. Steinhubl SR, Wolski K, Lincoff AM et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial. Circulation. 2001; 103:1403-9.

80. Topol EJ, Lincoff AM, Cohen E et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results for a multicentre randomised trial. Lancet. 1999; 354:2019-24.

81. Eli Lilly and Company. ReoPro (abciximab) injection for intravenous administration prescribing information. Indianapolis, IN; 1998 Feb 12.

82. Akkerhuis KM, Deckers JW, Lincoff AM et al. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA. 2001; 286:78-82.

87. Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein I blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998; 98:734-41.

88. Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000; 35: 915-21.

89. Simoons ML and GUSTO IV-ACS investigators. Effect of glycoprotein IIb/IIIa recptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial. Lancet. 2001; 357:1915-24.

90. Cohen M. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: GUSTO IV-ACS. Lancet. 2001; 357:1899-900.

91. Antman EM, Fox KM for the International Cardiology Forum. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. Am Heart J. 2000; 139:461-75.

92. Cairns J, Théroux P, Armstrong P et al. Unstable angina—Report from a Canadian expert round table. Can J Cardiol. 1996; 12:1279-92.

93. Armstrong PW. Pursuing progress in acute coronary syndromes. Circulation. 1999; 100:1586-9.

94. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol. 2000; 35:1699-702.

99. Goodman S. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-segement-elevation acute coronary syndrome: insights for the INTERACT trial. Am Heart J. 2005; 149:S73-80.

100. James S, Armstrong P, Califf R et al. Safety and efficacy of abciximab combined with dalteparin in the treatment of acute coronary syndromes. Eur Heart J. 2002; 23:1538-45.

101. Goodman SG, Fitchett D, Armstrong P et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfarctionated heparin in high-risk patients with non-ST-sgement elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003; 107:238-44.

103. Lansky AJ, Hochman JS, Ward PA et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professional from the American Heart Association. Circulation. 2005; 111:940-3.

104. Kastrati A, Mehilli J, Neumann FJ et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomzed trial. JAMA. 2006; 295:1531-8.

105. Moliterno DJ, Yabubov SJ, DiBattiste PM et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement: the TARGET follow-up study. Lancet. 2002; 360:355-60.

106. Eagle KA, Guyton RA, Davidoff R et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Available at: Accessed 2006 Nov 10.

111. Baroletti S, Hartman C, Churchill W. Visual compatibility of abciximab with selected drugs. Am J Health-Sys Pharm 2002; 59:466-7.

991. Anderson JL, Adams CD, Antman EM et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123:e426-579.

994. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58:e44-122.

995. Hamm CW, Bassand JP, Agewall S et al, for The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST -segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011; 32:2999-3054.

1016. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e89S-119S.

1100. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e344-426.

HID. Trissel LA. Handbook on injectable drugs. 13th ed; Bethesda, MD: American Society of Health-System Pharmacists; 2005:3.